Free Daily Podcast Summary
CURE SYNGAP1 PODCAST aka SYNGAP10: Daily Summaries Delivered
by Syngap Research Fund, 501(c)(3)
Over 1,600 families are caring for a loved one with the rare disease ”SynGAP” resulting from a variant of the SYNGAP1 gene. This weekly podcast is for them. -A quick summary of the latest news in the space. The host is Mike Graglia, co-founder & managing director of CURE SYNGAP1. CURE SYNGAP1 is a parent-led public charity in the US that strives to accelerate research into treatments for SYNGAP1 so that we can help our loved ones in a timeframe that matters.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 6 days ago9 min
1,871 #SYNGAP1 Census, COMBINEDBrain RR-RGND, Conference Dinner/Drinks & $200K Unlock Match #S10e222
Friday, October 2, 2026 — Week 40 CENSUS — 1,871 AND GROWING Q3 census: 1,871 known patients, +65 this quarter. First patient in Rwanda. USA +11, China +16, Brazil +6, France +4. Finding patients matters more than ever as trials approach. https://cureSYNGAP1.org/Census COMBINEDBRAIN — RARE RESEARCH ROUNDTABLE Wonderful Rare Research Roundtable on Genetic Neurodevelopmental Disorders. COMBINEDBrain is a gift to the rare neuro community — hug them when you see them. https://combinedbrain.org/RR-RGND Dr. Emma James of Encoded, chair of our IAB, posted about the meeting. https://www.linkedin.com/posts/emma-james-71759a1a_the-combinedbrain-research-roundtable-on-ugcPost-7511223599165472768-jDkI CURE SYNGAP1 CONFERENCE — DENVER 9 Family Legacy Sponsors, up from 8 in 2025. Thursday Rare Reception — free, register: https://cureSYNGAP1.org/RR26 Friday Family Dinner at Henry’s: https://cureSYNGAP1.org/Henrys Conference registration ends OCT. 31. https://cureSYNGAP1.org/Reg26 UNLOCK THEIR TOMORROW Q4 goal: $500,000 by Dec. 31, including a $200,000 match. Families can start their own fundraiser; anyone can donate. https://cureSYNGAP1.org/Unlock Your Idea. Your Fundraiser. Your SYNGAP1 Impact. https://curesyngap1.org/blog/your-idea-your-fundraiser-your-syngap1-impact COMMUNITY ACTION RARE Disease Week 2027, March 2-4, in DC. Travel reimbursement applications are open; deadline Nov. 6. https://bit.ly/4jo7fku RARE Foundation travel reimbursement post: https://www.facebook.com/share/p/1EeF8jTWFi • Sign up for ARI: https://cureSYNGAP1.org/Ari WARRIORS — JACK Jack is a 3-year-old from Berkeley who missed early milestones and was diagnosed with SYNGAP1 around age 3 after eyelid-fluttering episodes led to EEG, MRI and genetic testing. https://curesyngap1.org/syngap-warriors/jack-w NEWSLETTER #52 All the latest news and links in one place: https://cureSYNGAP1.org/NL52 Subscribe: https://cureSYNGAP1.org/Newsletter PUBMED + SCIENCE PubMed 2026: 54. +14 vs Week 40. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date USA - Use your ICD-10: F78.A1 SOCIAL MATTERS 5,301 LinkedIn. https://www.linkedin.com/company/cureSYNGAP1 1.63k YouTube. https://www.youtube.com/@CureSYNGAP1 11.0k X. https://twitter.com/cureSYNGAP1 43.4k Instagram. https://www.instagram.com/cureSYNGAP1 Like + subscribe wherever you listen. https://cureSYNGAP1.org/podcasts/syngap10 Episode 222 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy
- 1 weeks ago9 min
CAMP4 ASCEND Webinar + #SYNGAP1 Goes Global: Argentina, UN, Newborn Screening & Jaxon in ICU #S10E221
Saturday, September 26, 2026 — Week 39 CAMP4 ASCEND — WEBINAR #131 - SYNGAP1 ASCEND Phase 1/2 Trial: What You Need To Know. - Monday, Sept. 28 — 12 PM PT / 3 PM ET / 19:00 UTC. - Families: come hear directly from CAMP4 + ask your questions. https://cureSYNGAP1.org/AscendCT ARGENTINA — PATH TO THE CLINICAL TRIAL - CAMP4 + LATAM hybrid meeting: “Path to the Clinical Trial in Argentina.” - Remember how they got here: THE CONFERENCE. Community → relationships → trial readiness. - Recording: https://youtu.be/UuhOIzSEKH4 SYNGAP1 LEADERS REPRESENTING OUR COMMUNITY - Incoming Board Chair Eric Moulton at Newborn Screening Bootcamp in DC. Critical that SYNGAP1 is involved in NBS — find patients sooner. Thank you RARE Foundation. https://www.rareadvocates.org/newborn-screening-bootcamp/ - Vicky Arteaga + Allison Hirsch represented CURE SYNGAP1 at Rare Diseases International at the UN. https://www.linkedin.com/posts/rare-diseases-international_unga81-rarediseases-globalhealth-activity-7508918814357610496-xtZS WARRIORS - Wednesday Warrior #237: Matteo in NYC — happy 1st birthday! https://cureSYNGAP1.org/Warrior TAKE RESPIRATORY SERIOUSLY — JAXON IN ICU - Aaron Harding documented Jaxon’s ICU experience day-by-day. A difficult family experience worth reading directly. Add serrapeptase to your regime. - Aaron’s posts: https://www.facebook.com/aaron.j.harding.5 - Willsey paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11885846/ Another paper is coming soon. COMMUNITY IN ACTION - LATAM: One Voice for SYNGAP1 — VOCES! https://cureSYNGAP1.org/Voces - Auburn Delta Sigma Phi + Wyatt Jones: Delta Sig for SYNGAP1. https://cureSYNGAP1.org/auburn26 CURE SYNGAP1 CONFERENCE — DENVER - Dec. 3–4. Science Day: 156 registered. Family Day: 137, including 27 kids/Syngapians. - REGISTRATION ENDS OCT. 31. Hotel rooms going fast — register + book now. https://cureSYNGAP1.org/Reg26 PUBMED + SCIENCE - PubMed 2026: 54. +15 vs Week 39. Last year finished at 61, +9 vs the year. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date - NEW: Pekka Postila team — years of CURE SYNGAP1 support + partnership studying missense mutations. - Molecular modeling supports canonical RasGAP + Plexin-like RapGAP mechanisms; missense variants can disrupt protein stability AND catalysis; other insights. - Paper: https://doi.org/10.1016/j.yjsbx.2026.100162 USA: Use ICD-10 code F78.A1. SOCIAL MATTERS 5,288 LinkedIn. https://www.linkedin.com/company/cureSYNGAP1/ 1.62K YouTube. https://www.youtube.com/@CureSYNGAP1 11.1K X. https://twitter.com/cureSYNGAP1 43.7K Instagram. https://www.instagram.com/cureSYNGAP1/ Like + subscribe wherever you listen. https://cureSYNGAP1.org/podcasts/syngap10/ Episode 221 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy
- 2 weeks ago9 min
ASCEND Trial Webinar + #SYNGAP1 Warriors, Biobank, HEOR & Industry News #S10E220
Monday, September 21, 2026 — Week 39 CAMP4 ASCEND TRIAL — WEBINAR #131 CAMP4’s SYNGAP1 ASCEND Phase 1/2 Trial — What You Need To Know. Tuesday, Sept. 29 — 12 PM ET / 9 AM PT. REGISTER https://curesyngap1.org/calendar/webinar-131-camp4-syngap1-ascend-phase-1-2-trial/ SCRAMBLE FOR SYNGAP — 12 DAYS 5th Annual — Oct. 3, Greer, SC. Julie + family back on WSPA 7 News — including some very real family moments. SOLD OUT. Five years of building awareness + community. https://youtu.be/GcD58deUPtU Event: https://cureSYNGAP1.org/Scramble WARRIORS — KEEP TELLING THE STORIES NEW: Weston, 22 — diagnosed only 6 months ago. Late diagnosis! https://cureSYNGAP1.org/Warrior Will was Warrior #21 at age 9. He’s now 16. https://cureSYNGAP1.org/Will Kiera — Warrior #172 — now 6. https://cureSYNGAP1.org/Kiera These stories matter. Keep sharing them. COMBINEDBrain BIOBANK — ONLY 2 LOCATIONS LEFT Boston — Oct. 8–9. Denver — Dec. 3–4 at the CURE SYNGAP1 Conference. Email Lauren@cureSYNGAP1.org. HEOR — DOCUMENTING THE REAL BURDEN Building our Health Economics & Outcomes Research work with payers & clinicians in mind. Anxiety + behavior management matter. e.g. Rett: 323 caregivers — https://pubmed.ncbi.nlm.nih.gov/42570201/ e.g. Angelman: U.S. study of 105 caregivers estimated average annual caregiving economic impact at $79,837 — 53% from employment impacts/lost productivity. https://pubmed.ncbi.nlm.nih.gov/39985061/ HELP WANTED — PRESS We have a backlog of CURE SYNGAP1 press releases. Know PR / communications? We need help. Volunteer skills matter just as much as fundraising. IONIS — ANGELMAN Ionis published a community letter after the GTX-102/ASPIRE results. Relevant follow-up to my discussion in E217. Read it directly — 2’MOE https://assets.ctfassets.net/qj7dcdpo5rmb/nBQEr7TJQIyexzQu229Dl/a5ae4fff28861385532da0c8390b1c30/PA-US-AS-260005_-_Community_Statement_on_Status_of_Obudanersen_Program_-_FINAL_-_Sept_2026.pdf ULTRAGENYX — CONGRATULATIONS FDA FULL APPROVAL for FAYUVI / UX111 for Sanfilippo syndrome Type A. First-ever FDA-approved treatment for MPS IIIA. Single-dose IV AAV9 gene therapy. Second approved gene therapy for RARE. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-approval-fayuvitm-gene-therapy-first-ever UPCOMING SHOOT FOR SYNGAP1 — Nov. 14, Hurricane, UT https://cureSYNGAP1.org/Shoot FIGHT FOR FELIPE — Nov. 28, Boston https://cureSYNGAP1.org/Fight CURE SYNGAP1 CONFERENCE — Dec. 3–4, Denver https://cureSYNGAP1.org/Reg26 PUBMED 50 SYNGAP1 publications in 2026 — +11 vs. Week 39. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date USA: Use your ICD-10, F78.A1 SOCIAL MATTERS 5,268 LinkedIn — +28 since E219. https://www.linkedin.com/company/curesyngap1 1.62k Yo
- 3 weeks ago9 min
UK MHRA Approves CAMP4 ASCEND + USA Today + Rare-X/Citizen Health + 6 Things #S10E219
Friday, September 11, 2026 — Week 37 CAMP4 — ASCEND EXPANDS TO THE UK UK MHRA authorizes UK sites in CAMP4's Phase 1/2 CMP-002 trial. UK joins Australia + Argentina. EU filing remains under review. First-in-human trial still targeted to begin Q4 2026. Another major step toward our first disease-modifying clinical trial. https://investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-receives-authorization-united-kingdom-phase CAMP4 ANALYST DAY — SEPT. 28 12–1:30 PM ET. Trial design + unmet need + early pipeline. CURE SYNGAP1 participating https://investors.camp4tx.com/news-events/events We will have a day after, webinar, stay tuned for details. USA TODAY — SYNGAP1 IN PRINT SYNGAP1 family story appeared in USA TODAY's national print edition this week. Families need education, care + support TODAY. https://www.usatoday.com/story/life/health-wellness/2026/09/01/kids-special-education-school-shortage-care/90851980007/ RARE-X + CITIZEN HEALTH Global Genes selects Citizen Health technology to power RARE-X. Important for us: ProMMiS uses Rare-X; CURE SYNGAP1 already works with Citizen. https://www.prnewswire.com/news-releases/global-genes-partners-with-citizen-health-to-power-rare-x-302870871.html SIX THINGS U.S. FAMILIES CAN DO Our Take Action page is LIVE. Don't just read it. Keep coming back until you've done all six. https://curesyngap1.org/TakeAction IEP HELP — CITIZEN HEALTH Oct. 4: IEP deep dive + Q&A with Staci Zimmerman, M.Ed. Register https://curesyngap1.org/calendar/what-nobody-tells-you-about-ieps-citizen-health-webinar/ RESEARCH — HELP WANTED 2-year SYNGAP1 postdoc — Sapienza University of Rome. Patient iPSCs, cortical neurons + brain organoids. Deadline Sept. 30. Know someone? Amplify it. https://www.sins.it/job_offer/postdoctoral-position-available-at-sapienza-university-of-rome/ COMMUNITY QUICK HITS NEW WARRIOR: Felipe, age 3. Parents Brian + Alana organizing Fight for Felipe. Want to fundraise? New support form: https://cureSYNGAP1.org/Fundraise Café SYNGAP1 #40 + #41: GRIN2A + GRIN2B communities. https://cureSYNGAP1.org/Cafe Night of Impact recap live. Time to start planning the next one. https://cureSYNGAP1.org/SF26Recap UPCOMING EVENTS — COUNTDOWN SHOOT FOR SYNGAP1 — 64 DAYS November 14 — Hurricane, Utah Aiming for a Cure — Shooting for Hope https://cureSYNGAP1.org/Shoot FIGHT FOR FELIPE — 78 DAYS November 28 — Boston, Massachusetts https://cureSYNGAP1.org/Fight CURE SYNGAP1 CONFERENCE — 83 DAYS December 3–4 — Denver, Colorado https://cureSYNGAP1.org/Reg26 USA 🇺🇲: Use your ICD-10, F78.A1 SOCIAL MATTERS 5,240 LinkedIn — https://www.linkedin.com/company/curesyngap1 1.62k YouTube https://www.youtube.com/@CureSYNGAP1 43.7k Instagram https://www.instagram.com/curesyngap1 Like and subscribe to this podcast wherever you listen. https://cur
- Sep 8, 20269 min
USA Today, Synchrony Conf, #EEC2026, Portugal & Family Resources — #CureSYNGAP1 in Action #S10E218
Tuesday, September 8, 2026 — Week 37 DON’T MISS ASO UPDATE Episode 217 came out over the weekend. Don't miss it. There was lots of ASO news in there. https://www.linkedin.com/feed/update/urn:li:activity:7502544874399928322/ NATIONAL PRESS USA TODAY Special-needs care / education crisis — and a SYNGAP1 family featured. Diagnosis and future therapies aren't enough. Families need care, education and support today. https://www.linkedin.com/posts/bernadette-basilico-6924b29a_a-two-year-postdoctoral-position-with-share-7500493855591432192-sOD6/ https://www.usatoday.com/story/life/health-wellness/2026/09/01/kids-special-education-school-shortage-care/90851980007/ ADVOCACY UPDATE SYNCHRONY — PALO ALTO KAH + I attended the BRAIN Foundation's Synchrony symposium. The autism community is starting to wake up to neuroinflammation, and mental health psychiatrists are really working hard on this topic. There are also people looking more at the impact of diet. https://brainfoundation.org/synchrony-symposia/ ILAE #EEC2026 — ATHENS Virginie + Jaime + Vicky + Katrine representing SYNGAP1 at the 16th European Epilepsy Congress, Sept. 5–9. https://www.ilae.org/eec2026 Virginie’s Post: https://www.linkedin.com/posts/virginie-mcnamar_eec2026-ugcPost-7502600886368559105-LPbu/ THINGS YOU CAN DO RIGHT NOW GENEDX SURVEY How has getting a SYNGAP1 diagnosis improved your child's care? 5 minutes. Worth it. Please do it. https://curesyngap1.org/GDXsurvey ARI / CITIZEN HEALTH Sign up. Longitudinal medical records → research-ready data. This is clearly the future. https://citizen.health/ari/syngap1 SYNGO SYNGAP1 resource for families from LATAM, ask it to speak English! https://curesyngap1.org/syngo COMMUNITY GROWTH AND SUCCESS CURE SYNGAP1 PORTUGAL 🇵🇹 Congratulations to the Portuguese SYNGAP1 community — legal organization established + website live. Special applause for Henrique’s leadership. Another national organization building local advocacy and community. https://curegyngap1-portugal.org/en SCRAMBLE FOR SYNGAP — SOLD OUT Congratulations to the Scramble team — the 5th Annual Scramble for SYNGAP is SOLD OUT. 25 days to go. A great example of a community building momentum year after year. https://mailchi.mp/796f3e59d71b/the-scramble-for-syngap-is-sold-out?e=b5a3afc6ba UPCOMING EVENTS — COUNTDOWN SHOOT FOR SYNGAP1 — 67 DAYS November 14 — Hurricane, Utah Aiming for a Cure — Shooting for Hope https://cureSYNGAP1.org/Shoot FIGHT FOR FELIPE — 81 DAYS November 28 — Boston, Massachusetts https://cureSYNGAP1.org/Fight CURE SYNGAP1 CONFERENCE — 86 DAYS December 3–4 — Denver, Colorado https://cureSYNGAP1.org/Reg26 PUBMED 50 SYNGAP1 publications in 2026. +13 vs. Week 37. https://pubmed.ncbi.nlm.nih.gov/42692765/ Last year finished at 61 publications — +9 vs. the year. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date USA 🇺🇲: Use your ICD-10, F78.A1 SOCIAL MATTERS 5,220 LinkedIn — https://www.linkedin.com/company/curesyngap1 1.61k YouTube https://www.youtube.com/@CureSYNGAP1 11.1k X https://x.com/cureSYNGAP1 43.7k Instagram <a href
- Sep 6, 20269 min
#Angelman ASO Fails, #AlexanderDisease ASO Wins: #SYNGAP1 CAMP4 ASO? NYT on Clinical Trials #S10E217
Sunday, September 6, 2026 — Week 36 🛑 If you're reading this on social media, these show notes are going to get cut off. Please go to the podcast homepage and click on episode 217 to get the full show notes. https://curesyngap1.org/podcasts/syngap10 ALEXANDER DISEASE On September 3, the FDA approved ZANVASTRO — zilganersen — from Ionis (IONS) for Alexander disease. It is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the underlying protein buildup driving the disease. Alexander disease is caused by mutations in GFAP. Zilganersen reduces production of abnormal GFAP protein. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease ANGELMAN — ULTRAGENYX ASPIRE FAILS On September 2, Ultragenyx (RARE) announced results from its Phase 3 Aspire trial of apazunersen, formerly GTX-102, for Angelman syndrome. The trial failed its primary endpoint — change from baseline in Bayley-4 cognitive raw score. It also failed its key secondary endpoint — the Multidomain Responder Index, or MDRI. And there were no differences between the treated and control groups supporting efficacy in Bayley cognition, the MDRI, or any of the five individual domains that make up the MDRI. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-aspire-results-angelman-syndrome WHAT HAPPENED? Financial analyst take on the failure was brutal: “A complete double miss, with no data to argue about.” But this does not conclude that the underlying Angelman ASO strategy has been disproven. Broader read-through: “We think the mechanism still works, and the constraint was dose.” GTX-102 had a history of transient lower-extremity weakness. OAK HILL BIO (RACC) BASICALLY CALLED IT (Good to have multiple shots on goal.) Look at slides 10 and 11 of Oak Hill Bio's July investor presentation filed with the SEC. Oak Hill had already been making the case that the Angelman ASOs are not interchangeable. On slide 10, Oak Hill presents primate data showing nearly full restoration of paternal UBE3A production after a single dose of rugonersen, versus a much more modest reported effect from GTX-102. Importantly, Oak Hill itself notes that this was not a head-to-head study. Then look at slide 11. Oak Hill presents data claiming rugonersen is 20–100 times more potent at inducing UBE3A protein than the other Phase 3 Angelman ASOs. And its description of the Ultragenyx molecule is remarkably direct: “GTX-102 was dose limited.” These are Oak Hill's claims and company-presented preclinical data — but they made this argument before Aspire failed. https://www.sec.gov/Archives/edgar/data/2118032/000119312526316954/d101725dex992.htm THIS IS WHY PHASE 3 MATTERS Ultragenyx had encouraging earlier-stage data. Families appeared to be seeing improvements. Investigators saw improvements. The company saw improvements. Then came a randomized, sham-controlled Phase 3 trial. And it did not confirm efficacy. That is an important lesson for all of us in rare disease drug development: Phase 1/2 data are not Phase 3 data. THE NEW YORK TIMES — GETTING TO A CLINICAL TRIAL IS HARD There was also a New York Times piece this week that I think everyone following drug development should read. How extraordinarily difficult it has become to actually run clinical trials and get experimental medicines into patients. That means companies are looking outside the United States for places where trials can move more efficiently. CAMP4 has regulatory clearance to begin its first-in-human SYNGAP1 trial in Australia and Argentina. That's not an accident. The geography of clinical drug development is changing. The New York Times article is largely looking at this through the lens of cancer drug development today — but rare genetic disease is confronting the same challenges. Cancer today → rare genetic disease tomorrow. — read this article. NEW YORK TIMES — GIFT LINK: https://www.nytimes.com/2026/09/04/opinion/clinical-trials-drugs-science.html?unlocked_article_code=1.-lA.gxCw.n2L6DEBVdtFd&smid=nytcore-ios-share ANGELMAN COMMUNITY IS A MODEL One more thing. A failed Phase 3 trial is devastating for a patient community.
- Aug 31, 20269 min
Big Week for #SYNGAP1: Trials, Data, #Epilepsy, Palo Alto & Athens #S10E216
Sunday, August 30, 2026 — Week 36 TRIALS & DATA — CAMP4, RARE-X + ProMMiS CAMP4 / CMP-002 Australia and Argentina cleared. EU and UK filings underway. First-in-human Phase 1/2 study still targeted for Q4 2026. CMP-002 is designed to increase expression of the healthy SYNGAP1 copy. CAMP4 raised another $50M and reports cash runway through the end of 2028. Q2 earnings / corporate update: https://investors.camp4tx.com/news-releases/news-release-details/camp4-reports-second-quarter-2026-financial-results-and Rare-X + ProMMiS Rare-X is our PRO partner for the ProMMiS Natural History Study. IMPORTANT: Families participating in ProMMiS need to complete their Rare-X surveys within SEVEN DAYS of their ProMMiS Natural History Study visit date. We need the patient/caregiver-reported data to line up with the clinical visit data. ProMMiS: https://curesyngap1.org/resources/studies/syngap1-prommis/ Rare-X: https://cureSYNGAP1.org/RAREX ARI WEBINAR If you missed the Ari webinar, the recording is now available. https://cureSYNGAP1.org/AriWeb FUNDRAISE WITH US Please call us to set up your fundraisers. Please do not use Facebook fundraising unless it's an emergency. CURE SYNGAP1 ON THE ROAD — BRAIN FOUNDATION Kathryn and I are attending the BRAIN Foundation’s Synchrony 2026 scientific summit in Palo Alto. A chance for CURE SYNGAP1 to stay close to work happening across autism, neurology, genetics, biomarkers and therapeutics. https://brainfoundation.org/synchrony-symposia/ ILAE — EUROPEAN EPILEPSY CONGRESS Virginie is heading to Athens for the 16th European Epilepsy Congress, September 5–9. If you are going to be at the ILAE meeting in Athens, Greece, reach out to Virginie and connect with CURE SYNGAP1 in person. https://www.ilae.org/eec2026 UPCOMING EVENTS — COUNTDOWN SCRAMBLE FOR SYNGAP — 34 DAYS October 3 — Greer, South Carolina 5th Annual Scramble for Syngap https://cureSYNGAP1.org/Scramble SHOOT FOR SYNGAP1 — 76 DAYS November 14 — Hurricane, Utah Aiming for a Cure — Shooting for Hope https://cureSYNGAP1.org/Shoot FIGHT FOR FELIPE — 90 DAYS November 28 — Boston, Massachusetts https://cureSYNGAP1.org/Fight CURE SYNGAP1 CONFERENCE — 95 DAYS December 3–4 — Denver, Colorado Early bird pricing ends August 31! https://cureSYNGAP1.org/Reg26 PUBMED PubMed 2026 is at 49. +2 since Episode 214. +13 vs. the week. Last year finished at 61, +9 vs. the year. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date Coolest new paper: TBE on EEG. https://pubmed.ncbi.nlm.nih.gov/42620081/ USA 🇺🇲: Use your ICD-10, F78.A1 SOCIAL MATTERS 5,195 LinkedIn. +36 since Episode 214. https://www.linkedin.com/company/curesyngap1 1.61k YouTube. https://www.youtube.com/@CureSYNGAP1 11.1k Twitter https://twitter.com/cureSYNGAP1 43.7k Insta https://www.instagram.com/curesyngap1 Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10 Episode 216 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy
- Aug 30, 20269 min
#AdamsCamp & Tony in Denver: Support, Progress & Open Issues, taking a break from #LakeMary #S10e215
Tony with us for a week after five months away… Way less screen addicted More independent Chubby - Less exercise, worse food Depressed Adam’s Camp was great as usual The support model was striking: the camper-to-therapist ratio was close to one-to-one, with skilled professionals in speech, occupational, physical, and behavioral therapy. SYNGAP1 Connection at Camp! This was Tony’s fifth consecutive year at https://adamscamp.org/. That continuity made a difference. The Adam’s Camp team knew Tony well, and he was a known quantity to them. The team did a fabulous job. Even though Tony can be challenging at this age, and is bigger and sometimes aggressive, everything went smoothly at camp. More time in Denver. We visited Dr. Abbott at CHOC. For families looking for pediatric dental support in Denver, see Dr. Z at https://www.lakesidekidsdentistry.com/. Who will also start seeing kids at https://www.childrenscolorado.org/doctors-and-departments/departments/dental/ The hard parts There were still a couple of moments of aggression within our family. I do not want to pretend those moments disappeared; there is more work to do. The harder news came after Tony returned to school. His unhappiness about being there has increased after being with family, and it feels as though aggression may be moving in the wrong direction again. We are told this kind of transition is common for kids at his school, but that does not make the incident reports any less heartbreaking. Bringing him back was heartbreaking. Lorazepam. Open Questions What stayed with me is how well Tony did with people who knew him and a deeply skilled team supporting him. At his residential program, he also receives remarkable support. But at the end of the school year, he is expected to come home, and we are expected to recreate enough of that support with ABA and whatever additional help we can find. I do not have a neat conclusion. I am trying to understand what is best for Tony, what is best for John, and what is best for our whole family. I am sharing these questions because I suspect many families carry versions of them too. Related episodes & resources For the earlier Adam’s Camp conversation, watch #S10e110 https://www.youtube.com/watch?v=WBBEZPLRaBQ For the residential-care update, watch #S10e208 https://www.youtube.com/watch?v=ywDUuuGA8GA For a fuller personal conversation about this chapter in Tony’s life, listen to https://curesyngap1.org/podcasts/syngap1-stories/mike-graglia-may-2026-update Learn more about https://lakemary.org/. Both the Adam’s Camp team and Dr. Z from Lakeside will have a booth at the CURE SYNGAP1 Conference in Denver on December 3–4. Stop by to learn more and meet the team. https://curesyngap1.org/calendar/cure-syngap1-conference-2026-denver/ Like and subscribe to the CURE SYNGAP1 Podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10 Saturday, August 29, 2026 — Week 35 Episode 215 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy #Caregiving #DisabilitySupport #FamilyCaregiver #CaregiverSupport
Get CURE SYNGAP1 PODCAST aka SYNGAP10 summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
In the Interim...
Explores Bayesian statistics and adaptive clinical trial designs in medical research with insights from industry experts.
Tony Mantor: Why Not Me ?
Explores autism, mental health, and human stories to promote understanding, challenge stigma, and support neurodiversity.
Extend Podcast with Darshan Shah, MD
Explores science-backed strategies and expert insights to extend healthspan and optimize longevity through actionable health protocols.
Symptomatic: A Medical Mystery Podcast
Patients battle undiagnosed illnesses as host Lauren Bright Pacheco investigates their journeys to uncover hidden medical conditions.
Untold Stories: Life with a Severe Autoimmune Condition
People share personal experiences living with rare autoimmune conditions like myasthenia gravis and CIDP, discussing diagnosis, treatment, and daily challenges.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
Health Optimization Medicine Podcast
Experts discuss science-based strategies for health optimization, performance, and human potential through targeted interventions.
The Middle School Mary Poppins Podcast
Practical parenting strategies and brain science to help caregivers understand and support tweens through middle school challenges.
Data & Science with Glen Wright Colopy
Discusses healthcare technology with experts, focusing on data science and engineering innovations in clinical applications.
Sidenote by AsapSCIENCE
Greg and Mitch explore the science behind controversial topics using research and anecdotes to inform and entertain.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
About CURE SYNGAP1 PODCAST aka SYNGAP10
Over 1,600 families are caring for a loved one with the rare disease ”SynGAP” resulting from a variant of the SYNGAP1 gene. This weekly podcast is for them. -A quick summary of the latest news in the space. The host is Mike Graglia, co-founder & managing director of CURE SYNGAP1. CURE SYNGAP1 is a parent-led public charity in the US that strives to accelerate research into treatments for SYNGAP1 so that we can help our loved ones in a timeframe that matters.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from CURE SYNGAP1 PODCAST aka SYNGAP10 in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's CURE SYNGAP1 PODCAST aka SYNGAP10 daily summary?
It's a free AI-powered email that summarizes new episodes of CURE SYNGAP1 PODCAST aka SYNGAP10 as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the CURE SYNGAP1 PODCAST aka SYNGAP10 podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official CURE SYNGAP1 PODCAST aka SYNGAP10 product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Syngap Research Fund, 501(c)(3).
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does CURE SYNGAP1 PODCAST aka SYNGAP10 release new episodes?
CURE SYNGAP1 PODCAST aka SYNGAP10 publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does CURE SYNGAP1 PODCAST aka SYNGAP10 cover?
CURE SYNGAP1 PODCAST aka SYNGAP10 covers topics including Science, Business, Medicine, Fitness, Health & Fitness, Life Sciences, Non-Profit. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting CURE SYNGAP1 PODCAST aka SYNGAP10 summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.